US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

AN2 Therapeutics, Inc.

1.05

-0.0300-2.78%

Post-market: 1.050.00000.00%13:31 EDT

Volume:66.61K

Turnover:70.79K

Market Cap:31.68M

PE:-0.69

High:1.11

Open:1.05

Low:1.05

Close:1.08

Loading ...

Overview Company News Filings

AN2 Therapeutics completes 200-patient observational study in acute melioidosis

BRIEF-An2 Therapeutics To Initiate Phase 2 Trial Later This Year

AN2 Therapeutics Unveils Phase 2 Trial Plans for Epetraborole Following Key Insights from Melioidosis Study

AN2 Therapeutics Inc - to Initiate Phase 2 Trial Later This Year

THOMSON REUTERS

AN2 Therapeutics Reports Key Insights From 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole

THOMSON REUTERS

AN2 Therapeutics Inc. Executes Share Exchange Agreements with Coastlands Capital, Issuing Pre-Funded Warrants for 2.8 Million Shares

Michael Leonard, 10% Owner, Reports Disposal of Common Shares in AN2 Therapeutics Inc

Eric Easom, CEO of AN2 Therapeutics Inc., Reports Acquisition of Common Shares

10% Owner Leonard Braden Michael Reports Disposal of AN2 Therapeutics Inc. Common Shares

Director Margaret M. FitzPatrick reports acquisition of common shares of AN2 Therapeutics Inc

AN2 Therapeutics to Present Poster on Epetraborole's Activity Against M. Abscessus at Colorado Mycobacteria Conference

AN2 Therapeutics Inc. Conducted Annual Stockholders Meeting

BRIEF-AN2 Therapeutics Q1 Operating Expenses USD 11.537 Million

AN2 Therapeutics Reports Q1 2025 Financials: Net Loss Narrows to $10.6 Million, R&D Expenses Decrease to $7.7 Million

AN2 Therapeutics Q1 Operating Expenses USD 11.537 Million

THOMSON REUTERS

Bml Investment Partners-Sent Letter to AN2 Expressing Belief That Orderly Winddown, Liquidation, Capital Return Is in Best Interests of Shareholders

THOMSON REUTERS

Bml Investment Partners- Plans to Withhold Its Vote for All Three Directors at AN2's Upcoming Annual Meeting of Stockholders

THOMSON REUTERS

Bml Investment Partners Lp Reports 19.1% Stake in AN2 Therapeutics as of May 7 - SEC Filing

THOMSON REUTERS

AN2 Therapeutics Is Maintained at Market Outperform by JMP Securities

AN2 Therapeutics Inc - Ebo-301 Phase 3 Study Misses Primary Endpoint in Mac Lung Disease

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ANTX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ANTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANTX\",,,,,undefined,":{"symbol":"ANTX","market":"US","secType":"STK","nameCN":"AN2 Therapeutics, Inc.","latestPrice":1.05,"timestamp":1751562000000,"preClose":1.08,"halted":0,"volume":66614,"hourTrading":{"tag":"盘后","latestPrice":1.05,"preClose":1.05,"latestTime":"13:31 EDT","volume":3,"amount":3.1895,"timestamp":1751563902574},"delay":0,"floatShares":22041908,"shares":30175720,"eps":-1.516781,"marketStatus":"Market Closed","change":-0.03,"latestTime":"07-03 13:00:00 EDT","open":1.05,"high":1.11,"low":1.05,"amount":70788.824805,"amplitude":0.055556,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.516781,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751875200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1648180800000,"exchange":"NASDAQ","adjPreClose":1.08,"dividendRate":0.000952,"postHourTrading":{"tag":"盘后","latestPrice":1.05,"preClose":1.05,"latestTime":"13:31 EDT","volume":3,"amount":3.1895,"timestamp":1751563902574},"volumeRatio":1.6229765765081152},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANTX\",,,,,undefined,":{"symbol":"ANTX","floatShares":22041908,"roa":"-29.49%","roe":"-49.32%","lyrEps":-1.720551,"volumeRatio":1.6229765765081152,"shares":30175720,"dividePrice":0.001,"high":1.11,"amplitude":0.055556,"preClose":1.08,"low":1.05,"week52Low":0.87,"pbRate":"0.43","week52High":3.07,"institutionHeld":0,"latestPrice":1.05,"eps":-1.516781,"divideRate":0.000952,"volume":66614,"delay":0,"ttmEps":-1.516781,"open":1.05,"prevYearClose":1.38,"prevWeekClose":1.08,"prevMonthClose":1.06,"prevQuarterClose":1.06,"fiveDayClose":1.08,"twentyDayClose":1.09,"sixtyDayClose":1.24},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ANTX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2547096598","title":"AN2 Therapeutics completes 200-patient observational study in acute melioidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2547096598","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547096598?lang=en_us&edition=fundamental","pubTime":"2025-06-30 19:24","pubTimestamp":1751282691,"startTime":"0","endTime":"0","summary":"AN2 Therapeutics (ANTX) announced the completion of a 200-patient observational study in acute melioidosis, a highly lethal bacterial infection and...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/an2-therapeutics-completes-200-patient-observational-study-in-acute-melioidosis-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/an2-therapeutics-completes-200-patient-observational-study-in-acute-melioidosis-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","ANTX","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2547107095","title":"BRIEF-An2 Therapeutics To Initiate Phase 2 Trial Later This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2547107095","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547107095?lang=en_us&edition=fundamental","pubTime":"2025-06-30 19:21","pubTimestamp":1751282483,"startTime":"0","endTime":"0","summary":"BRIEF-An2 Therapeutics To Initiate Phase 2 Trial Later This YearJune 30 (Reuters) - AN2 Therapeutics Inc ANTX.O:AN2 THERAPEUTICS REPORTS KEY INSIGHTS FROM 200-PATIENT OBSERVATIONAL STUDY IN ACUTE MELI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nTUA6VMLZV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANTX"],"gpt_icon":0},{"id":"2547093795","title":"AN2 Therapeutics Unveils Phase 2 Trial Plans for Epetraborole Following Key Insights from Melioidosis Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2547093795","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547093795?lang=en_us&edition=fundamental","pubTime":"2025-06-30 19:01","pubTimestamp":1751281264,"startTime":"0","endTime":"0","summary":"AN2 Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced the completion of a 200-patient observational study in acute melioidosis, funded by the National Institutes of Health. The study, which took place in acute hospital settings across three endemic regions, evaluated patients receiving the current standard of care: IV meropenem or ceftazidime. Results revealed a high mortality rate of nearly 40% by Day 90, underscoring the severity of the disease and the limitations of existing treatments. The data gained from this study will inform the design of a Phase 2 proof-of-concept trial for epetraborole, a novel therapeutic being developed by AN2 Therapeutics. This trial is expected to begin later this year, aiming to address the urgent need for more effective treatment options for melioidosis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDL7dNDTt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANTX"],"gpt_icon":0},{"id":"2547093774","title":"AN2 Therapeutics Inc - to Initiate Phase 2 Trial Later This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2547093774","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547093774?lang=en_us&edition=fundamental","pubTime":"2025-06-30 19:00","pubTimestamp":1751281200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nTUA6VMLZV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANTX","BK4007"],"gpt_icon":0},{"id":"2547093268","title":"AN2 Therapeutics Reports Key Insights From 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole","url":"https://stock-news.laohu8.com/highlight/detail?id=2547093268","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547093268?lang=en_us&edition=fundamental","pubTime":"2025-06-30 19:00","pubTimestamp":1751281200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nTUA6VMLZV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANTX","BK4007"],"gpt_icon":0},{"id":"2544129238","title":"AN2 Therapeutics Inc. Executes Share Exchange Agreements with Coastlands Capital, Issuing Pre-Funded Warrants for 2.8 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2544129238","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544129238?lang=en_us&edition=fundamental","pubTime":"2025-06-20 19:01","pubTimestamp":1750417276,"startTime":"0","endTime":"0","summary":"AN2 Therapeutics Inc. Executes Share Exchange Agreements with Coastlands Capital, Issuing Pre-Funded Warrants for 2.8 Million Shares. AN2 Therapeutics Inc. has engaged in share transactions with Coastlands Capital Partners LP. On June 17, 2025, Coastlands Capital exchanged 2,500,000 shares of the company's common stock for a pre-funded warrant to acquire an equivalent number of shares. Similarly, on June 19, 2025, 300,000 shares of common stock were exchanged for a pre-funded warrant to acquire 300,000 shares. The pre-funded warrants have an exercise price of $0.00001 per share and are exercisable at any time until fully exercised.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDL8Vzkdh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANTX","BK4007"],"gpt_icon":0},{"id":"2544009036","title":"Michael Leonard, 10% Owner, Reports Disposal of Common Shares in AN2 Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2544009036","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544009036?lang=en_us&edition=fundamental","pubTime":"2025-06-17 03:41","pubTimestamp":1750102887,"startTime":"0","endTime":"0","summary":"Leonard Braden Michael, a 10% owner of AN2 Therapeutics Inc., reported a disposal of common shares. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 16, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nNDL69646Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Michael Leonard, 10% Owner, Reports Disposal of Common Shares in AN2 Therapeutics Inc","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANTX"],"gpt_icon":0},{"id":"2540702785","title":"Eric Easom, CEO of AN2 Therapeutics Inc., Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2540702785","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540702785?lang=en_us&edition=fundamental","pubTime":"2025-06-04 04:47","pubTimestamp":1748983637,"startTime":"0","endTime":"0","summary":"Eric Easom, Chief Executive Officer of AN2 Therapeutics Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250603:nNDL3ynw8B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Eric Easom, CEO of AN2 Therapeutics Inc., Reports Acquisition of Common Shares","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANTX"],"gpt_icon":0},{"id":"2539032562","title":"10% Owner Leonard Braden Michael Reports Disposal of AN2 Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2539032562","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539032562?lang=en_us&edition=fundamental","pubTime":"2025-05-31 05:41","pubTimestamp":1748641275,"startTime":"0","endTime":"0","summary":"Michael Leonard Braden, a 10% owner of AN2 Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 30, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250530:nNDL65bFF1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"10% Owner Leonard Braden Michael Reports Disposal of AN2 Therapeutics Inc. Common Shares","news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANTX","BK4007"],"gpt_icon":0},{"id":"2539295989","title":"Director Margaret M. FitzPatrick reports acquisition of common shares of AN2 Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2539295989","media":"Reuters","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539295989?lang=en_us&edition=fundamental","pubTime":"2025-05-30 04:18","pubTimestamp":1748549899,"startTime":"0","endTime":"0","summary":"Margaret M. FitzPatrick, a Director at AN2 Therapeutics Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL5fYNfJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANTX","BK4007"],"gpt_icon":0},{"id":"2539254490","title":"AN2 Therapeutics to Present Poster on Epetraborole's Activity Against M. Abscessus at Colorado Mycobacteria Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2539254490","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539254490?lang=en_us&edition=fundamental","pubTime":"2025-05-29 19:00","pubTimestamp":1748516422,"startTime":"0","endTime":"0","summary":"AN2 Therapeutics Inc., a biopharmaceutical company specializing in novel small molecule therapeutics, will present a poster at the Nontuberculous Mycobacteria Conference from May 27-30, 2025, at Colorado State University. The presentation, scheduled for May 29, will highlight the preclinical activity of epetraborole, a potential oral agent for Mycobacterium abscessus lung disease.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on May 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDL46pc5m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANTX"],"gpt_icon":0},{"id":"2538494504","title":"AN2 Therapeutics Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2538494504","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538494504?lang=en_us&edition=fundamental","pubTime":"2025-05-28 04:31","pubTimestamp":1748377873,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 27, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250527:nNDL1GNKG2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANTX","BK4007"],"gpt_icon":0},{"id":"2535081176","title":"BRIEF-AN2 Therapeutics Q1 Operating Expenses USD 11.537 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2535081176","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535081176?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:03","pubTimestamp":1747166619,"startTime":"0","endTime":"0","summary":"BRIEF-AN2 Therapeutics Q1 Operating Expenses USD 11.537 MillionMay 13 (Reuters) - AN2 Therapeutics Inc ANTX.O:AN2 THERAPEUTICS Q1 OPERATING EXPENSES USD 11.537 MILLIONAN2 THERAPEUTICS Q1 INCOME FROM O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nPLX11CC94:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANTX"],"gpt_icon":0},{"id":"2535908110","title":"AN2 Therapeutics Reports Q1 2025 Financials: Net Loss Narrows to $10.6 Million, R&D Expenses Decrease to $7.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2535908110","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535908110?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:01","pubTimestamp":1747166493,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on May 13, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nNDL85phvK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANTX"],"gpt_icon":0},{"id":"2535808197","title":"AN2 Therapeutics Q1 Operating Expenses USD 11.537 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2535808197","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535808197?lang=en_us&edition=fundamental","pubTime":"2025-05-14 04:01","pubTimestamp":1747166460,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nPLX11CC94:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANTX","BK4007"],"gpt_icon":0},{"id":"2533934054","title":"Bml Investment Partners-Sent Letter to AN2 Expressing Belief That Orderly Winddown, Liquidation, Capital Return Is in Best Interests of Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2533934054","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533934054?lang=en_us&edition=fundamental","pubTime":"2025-05-07 22:31","pubTimestamp":1746628276,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nFWN3RF36F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ANTX"],"gpt_icon":0},{"id":"2533932863","title":"Bml Investment Partners- Plans to Withhold Its Vote for All Three Directors at AN2's Upcoming Annual Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2533932863","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533932863?lang=en_us&edition=fundamental","pubTime":"2025-05-07 22:31","pubTimestamp":1746628276,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nFWN3RF36F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANTX","BK4007"],"gpt_icon":0},{"id":"2533347309","title":"Bml Investment Partners Lp Reports 19.1% Stake in AN2 Therapeutics as of May 7 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2533347309","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533347309?lang=en_us&edition=fundamental","pubTime":"2025-05-07 22:31","pubTimestamp":1746628276,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nFWN3RF36F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ANTX"],"gpt_icon":0},{"id":"2533587342","title":"AN2 Therapeutics Is Maintained at Market Outperform by JMP Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2533587342","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533587342?lang=en_us&edition=fundamental","pubTime":"2025-05-05 21:42","pubTimestamp":1746452520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 05, 2025 09:42 ET (13:42 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANTX","LENZ","JMP"],"gpt_icon":0},{"id":"2532988785","title":"AN2 Therapeutics Inc - Ebo-301 Phase 3 Study Misses Primary Endpoint in Mac Lung Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2532988785","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532988785?lang=en_us&edition=fundamental","pubTime":"2025-05-02 04:00","pubTimestamp":1746129612,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nFWN3R93EW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ANTX"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":46,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ANTX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ANTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ANTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.3333,"hold":0.3333,"sell":0.3333,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.3333,"analysts":3,"updateTime":1736481600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ANTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ANTX","date":"2025-07-03","current":-0.69862,"percent":0.825926,"low":-16.371108,"twenty":-8.248692,"median":-3.308058,"eighty":-0.71858,"high":-0.452319,"avg":-4.517882,"sd":3.933806,"marketCap":31684506},"quantilePoints":[{"date":"2022-03-25","current":-13.396124,"twenty":-13.256944,"median":-13.048173,"eighty":-12.797512,"marketCap":288592704},{"date":"2022-04-01","current":-13.735377,"twenty":-13.389165,"median":-13.082968,"eighty":-13.048173,"marketCap":295901220},{"date":"2022-04-08","current":-13.126462,"twenty":-13.389165,"median":-13.126462,"eighty":-13.048173,"marketCap":282783370},{"date":"2022-04-14","current":-12.195692,"twenty":-13.35611,"median":-13.056872,"eighty":-12.282634,"marketCap":262731799},{"date":"2022-04-22","current":-12.674125,"twenty":-13.265642,"median":-13.043824,"eighty":-12.188734,"marketCap":273038682},{"date":"2022-04-29","current":-13.596196,"twenty":-13.35611,"median":-13.048173,"eighty":-12.282634,"marketCap":292902855},{"date":"2022-05-06","current":-16.371108,"twenty":-13.735377,"median":-13.082968,"eighty":-12.639148,"marketCap":352682772},{"date":"2022-05-13","current":-12.634954,"twenty":-13.707541,"median":-13.048173,"eighty":-12.337661,"marketCap":343038993},{"date":"2022-05-20","current":-7.432326,"twenty":-13.556182,"median":-13.043824,"eighty":-12.180035,"marketCap":201787643},{"date":"2022-05-27","current":-10.426695,"twenty":-13.392645,"median":-13.013378,"eighty":-11.61546,"marketCap":283084780},{"date":"2022-06-03","current":-11.20566,"twenty":-13.378727,"median":-12.769812,"eighty":-10.726847,"marketCap":304233677},{"date":"2022-06-10","current":-6.882048,"twenty":-13.265642,"median":-12.632679,"eighty":-9.433336,"marketCap":186847596},{"date":"2022-06-17","current":-6.081643,"twenty":-13.265642,"median":-12.334802,"eighty":-8.368513,"marketCap":165116619},{"date":"2022-06-24","current":-6.253159,"twenty":-13.196052,"median":-12.186994,"eighty":-7.795366,"marketCap":169773257},{"date":"2022-07-01","current":-5.831517,"twenty":-13.172482,"median":-12.113054,"eighty":-7.105018,"marketCap":158325689},{"date":"2022-07-08","current":-6.424674,"twenty":-13.15991,"median":-11.715613,"eighty":-6.370361,"marketCap":174429895},{"date":"2022-07-15","current":-6.360356,"twenty":-13.1369,"median":-11.019852,"eighty":-6.253159,"marketCap":172683656},{"date":"2022-07-22","current":-5.881542,"twenty":-13.116023,"median":-10.573198,"eighty":-6.184553,"marketCap":159683875},{"date":"2022-07-29","current":-6.117376,"twenty":-13.077749,"median":-9.433336,"eighty":-5.990169,"marketCap":166086752},{"date":"2022-08-05","current":-7.28225,"twenty":-13.051653,"median":-8.550748,"eighty":-5.92728,"marketCap":197713085},{"date":"2022-08-12","current":-11.654946,"twenty":-13.048173,"median":-8.368513,"eighty":-5.964441,"marketCap":376023512},{"date":"2022-08-19","current":-11.973683,"twenty":-13.048173,"median":-8.836607,"eighty":-5.990169,"marketCap":386306920},{"date":"2022-08-26","current":-9.447843,"twenty":-13.042954,"median":-9.447843,"eighty":-6.034477,"marketCap":304815757},{"date":"2022-09-02","current":-7.685769,"twenty":-13.039474,"median":-9.296256,"eighty":-6.073067,"marketCap":247965969},{"date":"2022-09-09","current":-5.683139,"twenty":-13.031725,"median":-8.930422,"eighty":-5.955866,"marketCap":183355118},{"date":"2022-09-16","current":-5.310277,"twenty":-13.017412,"median":-8.532882,"eighty":-5.851527,"marketCap":171325470},{"date":"2022-09-23","current":-6.735572,"twenty":-12.958334,"median":-8.22201,"eighty":-5.820083,"marketCap":217309769},{"date":"2022-09-30","current":-10.452165,"twenty":-12.87166,"median":-8.485618,"eighty":-5.827229,"marketCap":337218196},{"date":"2022-10-07","current":-10.758874,"twenty":-12.827224,"median":-8.662429,"eighty":-5.851527,"marketCap":347113551},{"date":"2022-10-14","current":-10.75286,"twenty":-12.732811,"median":-9.159176,"eighty":-5.887259,"marketCap":346919525},{"date":"2022-10-21","current":-9.868816,"twenty":-12.676035,"median":-9.377444,"eighty":-5.901552,"marketCap":318397617},{"date":"2022-10-28","current":-9.056939,"twenty":-12.658457,"median":-9.321551,"eighty":-5.921562,"marketCap":292204029},{"date":"2022-11-04","current":-9.604204,"twenty":-12.633134,"median":-9.294488,"eighty":-5.955866,"marketCap":309860448},{"date":"2022-11-11","current":-7.870305,"twenty":-12.51788,"median":-9.213301,"eighty":-5.98731,"marketCap":288517524},{"date":"2022-11-18","current":-6.891148,"twenty":-12.343378,"median":-9.131888,"eighty":-6.021613,"marketCap":252622607},{"date":"2022-11-25","current":-5.8326,"twenty":-12.30698,"median":-9.032884,"eighty":-5.94729,"marketCap":213817291},{"date":"2022-12-02","current":-5.102202,"twenty":-12.193952,"median":-8.756244,"eighty":-5.842388,"marketCap":187041623},{"date":"2022-12-09","current":-4.726417,"twenty":-12.185254,"median":-8.550748,"eighty":-5.80579,"marketCap":173265735},{"date":"2022-12-16","current":-5.181593,"twenty":-12.178295,"median":-8.404872,"eighty":-5.725749,"marketCap":189952021},{"date":"2022-12-23","current":-5.043982,"twenty":-12.152199,"median":-8.130215,"eighty":-5.685509,"marketCap":184907330},{"date":"2022-12-30","current":-5.043982,"twenty":-12.047813,"median":-8.043349,"eighty":-5.617123,"marketCap":184907330},{"date":"2023-01-06","current":-5.361546,"twenty":-11.988509,"median":-7.887149,"eighty":-5.544229,"marketCap":196548925},{"date":"2023-01-13","current":-5.642062,"twenty":-11.900765,"median":-7.790914,"eighty":-5.514548,"marketCap":206832334},{"date":"2023-01-20","current":-5.292741,"twenty":-11.857841,"median":-7.780329,"eighty":-5.486455,"marketCap":194026580},{"date":"2023-01-27","current":-6.652975,"twenty":-11.83416,"median":-7.52668,"eighty":-5.481434,"marketCap":243891411},{"date":"2023-02-03","current":-8.256675,"twenty":-11.724707,"median":-7.50379,"eighty":-5.486455,"marketCap":302681464},{"date":"2023-02-10","current":-7.621547,"twenty":-11.591193,"median":-7.550498,"eighty":-5.497097,"marketCap":279398275},{"date":"2023-02-17","current":-7.224591,"twenty":-11.42481,"median":-7.520984,"eighty":-5.503782,"marketCap":264846281},{"date":"2023-02-24","current":-6.409509,"twenty":-11.289301,"median":-7.50379,"eighty":-5.509499,"marketCap":234966188},{"date":"2023-03-03","current":-5.456816,"twenty":-11.208214,"median":-7.426374,"eighty":-5.509499,"marketCap":200041403},{"date":"2023-03-10","current":-4.578221,"twenty":-11.173685,"median":-7.303982,"eighty":-5.480511,"marketCap":167832991},{"date":"2023-03-17","current":-4.684075,"twenty":-11.125722,"median":-7.239128,"eighty":-5.439451,"marketCap":171713523},{"date":"2023-03-24","current":-5.493865,"twenty":-11.125722,"median":-7.16076,"eighty":-5.330785,"marketCap":201399590},{"date":"2023-03-31","current":-4.675853,"twenty":-11.084828,"median":-7.064148,"eighty":-5.270511,"marketCap":191504234},{"date":"2023-04-06","current":-4.230534,"twenty":-11.023486,"median":-6.924927,"eighty":-5.260984,"marketCap":173265735},{"date":"2023-04-14","current":-4.216321,"twenty":-11.019852,"median":-6.821303,"eighty":-5.202027,"marketCap":172683656},{"date":"2023-04-21","current":-4.007874,"twenty":-10.916914,"median":-6.735572,"eighty":-5.163355,"marketCap":164146486},{"date":"2023-04-28","current":-3.789856,"twenty":-10.785335,"median":-6.531871,"eighty":-5.110953,"marketCap":155217351},{"date":"2023-05-04","current":-2.741598,"twenty":-10.756468,"median":-6.516471,"eighty":-5.079973,"marketCap":112284892},{"date":"2023-05-12","current":-2.021591,"twenty":-10.742455,"median":-6.4889,"eighty":-5.044655,"marketCap":98297847},{"date":"2023-05-19","current":-3.128272,"twenty":-10.723989,"median":-6.417091,"eighty":-5.017615,"marketCap":152109119},{"date":"2023-05-26","current":-2.225348,"twenty":-10.658392,"median":-6.345996,"eighty":-4.977293,"marketCap":108205337},{"date":"2023-06-02","current":-2.385158,"twenty":-10.566429,"median":-6.281745,"eighty":-4.901078,"marketCap":115975918},{"date":"2023-06-09","current":-2.560948,"twenty":-10.530346,"median":-6.253159,"eighty":-4.858736,"marketCap":124523557},{"date":"2023-06-16","current":-2.916525,"twenty":-10.482234,"median":-6.179275,"eighty":-4.763467,"marketCap":141813099},{"date":"2023-06-23","current":-2.816644,"twenty":-10.458179,"median":-6.099509,"eighty":-4.692657,"marketCap":136956486},{"date":"2023-06-30","current":-3.356001,"twenty":-10.436883,"median":-6.046964,"eighty":-4.666378,"marketCap":163182196},{"date":"2023-07-07","current":-3.515811,"twenty":-10.412827,"median":-5.988739,"eighty":-4.546389,"marketCap":170952777},{"date":"2023-07-14","current":-3.096311,"twenty":-10.358348,"median":-5.938714,"eighty":-4.379111,"marketCap":150555003},{"date":"2023-07-21","current":-3.096311,"twenty":-10.284978,"median":-5.895835,"eighty":-4.25703,"marketCap":150555003},{"date":"2023-07-28","current":-3.268106,"twenty":-10.193567,"median":-5.832059,"eighty":-4.205213,"marketCap":158908377},{"date":"2023-08-04","current":-3.216168,"twenty":-10.158686,"median":-5.817224,"eighty":-4.029666,"marketCap":156382938},{"date":"2023-08-11","current":-3.356001,"twenty":-10.014353,"median":-5.791146,"eighty":-3.845856,"marketCap":163182196},{"date":"2023-08-18","current":-5.688753,"twenty":-9.981877,"median":-5.731467,"eighty":-3.79935,"marketCap":308944792},{"date":"2023-08-25","current":-8.204932,"twenty":-9.916927,"median":-5.791146,"eighty":-3.845856,"marketCap":445593450},{"date":"2023-09-01","current":-8.226812,"twenty":-9.859194,"median":-5.817224,"eighty":-3.898925,"marketCap":446781699},{"date":"2023-09-08","current":-8.50578,"twenty":-9.820705,"median":-5.831517,"eighty":-3.974712,"marketCap":461931876},{"date":"2023-09-15","current":-7.915024,"twenty":-9.604204,"median":-5.888688,"eighty":-4.007874,"marketCap":429849148},{"date":"2023-09-22","current":-7.554007,"twenty":-9.586163,"median":-5.938714,"eighty":-4.029192,"marketCap":410243036},{"date":"2023-09-29","current":-8.730048,"twenty":-9.561973,"median":-5.988739,"eighty":-4.031561,"marketCap":474111430},{"date":"2023-10-06","current":-8.292451,"twenty":-9.447843,"median":-6.060204,"eighty":-4.121573,"marketCap":450346446},{"date":"2023-10-13","current":-8.068183,"twenty":-9.447843,"median":-6.108187,"eighty":-4.154735,"marketCap":438166892},{"date":"2023-10-20","current":-7.958784,"twenty":-9.433336,"median":-6.21897,"eighty":-4.202436,"marketCap":432225646},{"date":"2023-10-27","current":-8.062713,"twenty":-9.388622,"median":-6.246012,"eighty":-4.20799,"marketCap":437869830},{"date":"2023-11-03","current":-8.204932,"twenty":-9.299901,"median":-6.263879,"eighty":-4.222006,"marketCap":445593450},{"date":"2023-11-10","current":-8.42373,"twenty":-9.245776,"median":-6.345996,"eighty":-4.238114,"marketCap":457475942},{"date":"2023-11-17","current":-8.188416,"twenty":-9.191651,"median":-6.417091,"eighty":-4.251835,"marketCap":488651941},{"date":"2023-11-24","current":-8.592106,"twenty":-9.159176,"median":-6.462436,"eighty":-4.25703,"marketCap":512742511},{"date":"2023-12-01","current":-8.756572,"twenty":-9.148261,"median":-6.515364,"eighty":-4.263696,"marketCap":522557188},{"date":"2023-12-08","current":-9.369582,"twenty":-9.256601,"median":-6.592423,"eighty":-4.286376,"marketCap":559139166},{"date":"2023-12-15","current":-10.181945,"twenty":-9.420585,"median":-6.735572,"eighty":-4.378104,"marketCap":607617721},{"date":"2023-12-22","current":-10.216831,"twenty":-9.539147,"median":-6.886598,"eighty":-4.40653,"marketCap":609699622},{"date":"2023-12-29","current":-10.416184,"twenty":-9.612102,"median":-6.924927,"eighty":-4.479724,"marketCap":621596200},{"date":"2024-01-05","current":-9.638708,"twenty":-9.641698,"median":-7.064148,"eighty":-4.516825,"marketCap":575199546},{"date":"2024-01-12","current":-10.431136,"twenty":-9.849572,"median":-7.123402,"eighty":-4.535879,"marketCap":622488443},{"date":"2024-01-19","current":-9.892883,"twenty":-9.923734,"median":-7.161078,"eighty":-4.541134,"marketCap":590367683},{"date":"2024-01-26","current":-9.912818,"twenty":-9.910825,"median":-7.239128,"eighty":-4.565367,"marketCap":591557341},{"date":"2024-02-02","current":-9.937737,"twenty":-9.925728,"median":-7.28225,"eighty":-4.59301,"marketCap":593044413},{"date":"2024-02-09","current":-9.96764,"twenty":-9.966643,"median":-7.362202,"eighty":-4.656903,"marketCap":594828900},{"date":"2024-02-16","current":-1.918771,"twenty":-9.966643,"median":-7.303982,"eighty":-4.541134,"marketCap":114504563},{"date":"2024-02-23","current":-1.649644,"twenty":-9.962656,"median":-7.2641,"eighty":-4.382132,"marketCap":98444182},{"date":"2024-03-01","current":-1.485178,"twenty":-9.942721,"median":-7.216995,"eighty":-4.255363,"marketCap":88629506},{"date":"2024-03-08","current":-1.465243,"twenty":-9.937737,"median":-7.16076,"eighty":-4.202436,"marketCap":87439848},{"date":"2024-03-15","current":-1.515081,"twenty":-9.928955,"median":-7.0934,"eighty":-4.029192,"marketCap":90413992},{"date":"2024-03-22","current":-1.649644,"twenty":-9.912818,"median":-6.924927,"eighty":-3.837326,"marketCap":98444182},{"date":"2024-03-28","current":-1.60479,"twenty":-9.904844,"median":-6.882048,"eighty":-3.54138,"marketCap":95767452},{"date":"2024-04-05","current":-1.493229,"twenty":-9.894877,"median":-6.735572,"eighty":-3.40709,"marketCap":96659696},{"date":"2024-04-12","current":-1.379706,"twenty":-9.873629,"median":-6.531871,"eighty":-3.34002,"marketCap":89311125},{"date":"2024-04-19","current":-1.094567,"twenty":-9.830327,"median":-6.512717,"eighty":-3.300068,"marketCap":70853492},{"date":"2024-04-26","current":-1.048577,"twenty":-9.7389,"median":-6.435973,"eighty":-3.275297,"marketCap":67876455},{"date":"2024-05-03","current":-1.170453,"twenty":-9.714462,"median":-6.384932,"eighty":-3.243335,"marketCap":75765761},{"date":"2024-05-10","current":-1.138196,"twenty":-9.689543,"median":-6.288891,"eighty":-3.200986,"marketCap":73677728},{"date":"2024-05-17","current":-1.025534,"twenty":-9.683563,"median":-6.253159,"eighty":-3.153842,"marketCap":67711920},{"date":"2024-05-24","current":-0.908072,"twenty":-9.651666,"median":-6.21897,"eighty":-3.096311,"marketCap":59956370},{"date":"2024-05-31","current":-0.899037,"twenty":-9.640702,"median":-6.117376,"eighty":-3.032764,"marketCap":59359789},{"date":"2024-06-07","current":-0.917108,"twenty":-9.626747,"median":-6.070923,"eighty":-2.970061,"marketCap":60552951},{"date":"2024-06-14","current":-0.980356,"twenty":-9.610032,"median":-5.995886,"eighty":-2.875774,"marketCap":64729016},{"date":"2024-06-21","current":-0.95325,"twenty":-9.596988,"median":-5.970211,"eighty":-2.763626,"marketCap":62939274},{"date":"2024-06-28","current":-0.971321,"twenty":-9.576487,"median":-5.902982,"eighty":-2.560948,"marketCap":64132436},{"date":"2024-07-05","current":-1.188174,"twenty":-9.555391,"median":-5.857071,"eighty":-2.458418,"marketCap":78450375},{"date":"2024-07-12","current":-1.165585,"twenty":-9.514113,"median":-5.824371,"eighty":-2.36598,"marketCap":76958923},{"date":"2024-07-19","current":-1.260458,"twenty":-9.453014,"median":-5.802931,"eighty":-2.238133,"marketCap":83223021},{"date":"2024-07-26","current":-1.210763,"twenty":-9.447843,"median":-5.737331,"eighty":-2.128663,"marketCap":79941827},{"date":"2024-08-02","current":-1.165585,"twenty":-9.447142,"median":-5.721772,"eighty":-1.927742,"marketCap":76958923},{"date":"2024-08-09","current":-0.46533,"twenty":-9.442138,"median":-5.694989,"eighty":-1.744863,"marketCap":30723911},{"date":"2024-08-16","current":-0.452319,"twenty":-9.420585,"median":-5.683771,"eighty":-1.649644,"marketCap":29245582},{"date":"2024-08-23","current":-0.507705,"twenty":-9.368585,"median":-5.668525,"eighty":-1.569679,"marketCap":32826674},{"date":"2024-08-30","current":-0.521551,"twenty":-9.363601,"median":-5.629593,"eighty":-1.541673,"marketCap":33721947},{"date":"2024-09-06","current":-0.470781,"twenty":-9.359614,"median":-5.566854,"eighty":-1.505114,"marketCap":30439279},{"date":"2024-09-13","current":-0.480012,"twenty":-9.321551,"median":-5.545658,"eighty":-1.493229,"marketCap":31036128},{"date":"2024-09-20","current":-0.484627,"twenty":-9.274889,"median":-5.510762,"eighty":-1.470227,"marketCap":31334552},{"date":"2024-09-27","current":-0.489243,"twenty":-9.269905,"median":-5.493865,"eighty":-1.445308,"marketCap":31632976},{"date":"2024-10-04","current":-0.493858,"twenty":-9.267426,"median":-5.480973,"eighty":-1.398102,"marketCap":31931401},{"date":"2024-10-11","current":-0.484627,"twenty":-9.213301,"median":-5.440937,"eighty":-1.379706,"marketCap":31334552},{"date":"2024-10-18","current":-0.484627,"twenty":-9.159176,"median":-5.400004,"eighty":-1.260458,"marketCap":31334552},{"date":"2024-10-25","current":-0.493858,"twenty":-9.159176,"median":-5.292741,"eighty":-1.224316,"marketCap":31931401},{"date":"2024-11-01","current":-0.498474,"twenty":-9.104599,"median":-5.27157,"eighty":-1.192692,"marketCap":32229825},{"date":"2024-11-08","current":-0.507705,"twenty":-9.056939,"median":-5.260984,"eighty":-1.175061,"marketCap":32826674},{"date":"2024-11-15","current":-0.492263,"twenty":-9.008828,"median":-5.223935,"eighty":-1.165585,"marketCap":29878890},{"date":"2024-11-22","current":-0.659632,"twenty":-8.984772,"median":-5.186886,"eighty":-1.152032,"marketCap":40037712},{"date":"2024-11-29","current":-0.822079,"twenty":-8.833504,"median":-5.165715,"eighty":-1.14661,"marketCap":49897746},{"date":"2024-12-06","current":-0.708859,"twenty":-8.764395,"median":-5.131312,"eighty":-1.135958,"marketCap":43025601},{"date":"2024-12-13","current":-0.703936,"twenty":-8.75631,"median":-5.107495,"eighty":-1.128429,"marketCap":42726812},{"date":"2024-12-20","current":-0.620251,"twenty":-8.752791,"median":-5.06243,"eighty":-1.10594,"marketCap":37647401},{"date":"2024-12-27","current":-0.708859,"twenty":-8.7388,"median":-5.051921,"eighty":-1.093587,"marketCap":43025601},{"date":"2025-01-03","current":-0.699014,"twenty":-8.706848,"median":-5.044823,"eighty":-1.083887,"marketCap":42428023},{"date":"2025-01-10","current":-0.615329,"twenty":-8.669427,"median":-5.041335,"eighty":-1.044599,"marketCap":37348612},{"date":"2025-01-17","current":-0.625174,"twenty":-8.655656,"median":-5.006933,"eighty":-1.011077,"marketCap":37946190},{"date":"2025-01-24","current":-0.615329,"twenty":-8.642528,"median":-4.99154,"eighty":-0.978098,"marketCap":37348612},{"date":"2025-01-31","current":-0.56118,"twenty":-8.620649,"median":-4.940774,"eighty":-0.957768,"marketCap":34061934},{"date":"2025-02-07","current":-0.531644,"twenty":-8.592106,"median":-4.895785,"eighty":-0.948732,"marketCap":32269201},{"date":"2025-02-14","current":-0.551335,"twenty":-8.592106,"median":-4.864028,"eighty":-0.935179,"marketCap":33464356},{"date":"2025-02-21","current":-0.556257,"twenty":-8.573312,"median":-4.805808,"eighty":-0.928854,"marketCap":33763145},{"date":"2025-02-28","current":-0.56118,"twenty":-8.566482,"median":-4.763467,"eighty":-0.907168,"marketCap":34061934},{"date":"2025-03-07","current":-0.644865,"twenty":-8.539495,"median":-4.726229,"eighty":-0.899037,"marketCap":39141345},{"date":"2025-03-14","current":-0.689168,"twenty":-8.528704,"median":-4.684075,"eighty":-0.782698,"marketCap":41830446},{"date":"2025-03-21","current":-0.718704,"twenty":-8.510156,"median":-4.66401,"eighty":-0.732487,"marketCap":43623179},{"date":"2025-03-28","current":-0.815207,"twenty":-8.48965,"median":-4.562154,"eighty":-0.73741,"marketCap":41837220},{"date":"2025-04-04","current":-0.744829,"twenty":-8.484244,"median":-4.520001,"eighty":-0.742333,"marketCap":38225374},{"date":"2025-04-11","current":-0.750694,"twenty":-8.45484,"median":-4.377097,"eighty":-0.733398,"marketCap":38526361},{"date":"2025-04-17","current":-0.738964,"twenty":-8.433268,"median":-4.263696,"eighty":-0.736426,"marketCap":37924387},{"date":"2025-04-25","current":-0.7331,"twenty":-8.412415,"median":-4.240009,"eighty":-0.733323,"marketCap":37623400},{"date":"2025-05-02","current":-0.715505,"twenty":-8.383057,"median":-4.202436,"eighty":-0.728023,"marketCap":36720438},{"date":"2025-05-09","current":-0.703776,"twenty":-8.368106,"median":-4.076567,"eighty":-0.727235,"marketCap":36118464},{"date":"2025-05-16","current":-0.803022,"twenty":-8.352142,"median":-4.007874,"eighty":-0.727235,"marketCap":36419451},{"date":"2025-05-23","current":-0.789749,"twenty":-8.341681,"median":-3.858652,"eighty":-0.727235,"marketCap":35817476},{"date":"2025-05-30","current":-0.805076,"twenty":-8.337305,"median":-3.749538,"eighty":-0.727235,"marketCap":36512621},{"date":"2025-06-06","current":-0.738541,"twenty":-8.328553,"median":-3.531792,"eighty":-0.727235,"marketCap":33495049},{"date":"2025-06-13","current":-0.751848,"twenty":-8.312143,"median":-3.453864,"eighty":-0.727235,"marketCap":34098563},{"date":"2025-06-20","current":-0.731887,"twenty":-8.285296,"median":-3.37993,"eighty":-0.727235,"marketCap":33193292},{"date":"2025-06-27","current":-0.71858,"twenty":-8.255078,"median":-3.34002,"eighty":-0.72001,"marketCap":32589777},{"date":"2025-07-03","current":-0.69862,"twenty":-8.248692,"median":-3.308058,"eighty":-0.71858,"marketCap":31684506}],"updateTime":1751818052226}}}